MX2022011039A - Sistemas crispr clase ii tipo v. - Google Patents

Sistemas crispr clase ii tipo v.

Info

Publication number
MX2022011039A
MX2022011039A MX2022011039A MX2022011039A MX2022011039A MX 2022011039 A MX2022011039 A MX 2022011039A MX 2022011039 A MX2022011039 A MX 2022011039A MX 2022011039 A MX2022011039 A MX 2022011039A MX 2022011039 A MX2022011039 A MX 2022011039A
Authority
MX
Mexico
Prior art keywords
class
type
crispr systems
systems
crispr
Prior art date
Application number
MX2022011039A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Brown
Brian Thomas
Audra Devoto
Cristina Butterfield
Lisa Alexander
Daniela S A Goltsman
Justine Albers
Alan Brooks
Greg Cost
Morayma Temoche-Diaz
Cindy Castelle
Rebecca Lamothe
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of MX2022011039A publication Critical patent/MX2022011039A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1068Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Amplifiers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022011039A 2020-03-06 2021-03-06 Sistemas crispr clase ii tipo v. MX2022011039A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062986477P 2020-03-06 2020-03-06
US202063022276P 2020-05-08 2020-05-08
US202063045815P 2020-06-29 2020-06-29
US202063068316P 2020-08-20 2020-08-20
US202063069699P 2020-08-24 2020-08-24
US202063116157P 2020-11-19 2020-11-19
PCT/US2021/021259 WO2021178933A2 (en) 2020-03-06 2021-03-06 Class ii, type v crispr systems

Publications (1)

Publication Number Publication Date
MX2022011039A true MX2022011039A (es) 2022-12-13

Family

ID=77612848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011039A MX2022011039A (es) 2020-03-06 2021-03-06 Sistemas crispr clase ii tipo v.

Country Status (10)

Country Link
US (3) US11713471B2 (https=)
EP (1) EP4114932A4 (https=)
JP (2) JP7605852B2 (https=)
KR (2) KR102647766B1 (https=)
CN (1) CN116096876A (https=)
AU (2) AU2021231074C1 (https=)
CA (1) CA3174557A1 (https=)
GB (2) GB2617658B (https=)
MX (1) MX2022011039A (https=)
WO (1) WO2021178933A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
GB2617658B (en) 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
JP2023548588A (ja) * 2020-10-30 2023-11-17 アーバー バイオテクノロジーズ, インコーポレイテッド Tracを標的とするrnaガイドを含む組成物及びその使用
US20230072431A1 (en) * 2020-11-03 2023-03-09 Science Solutions Llc Novel class 2 crispr-cas rna-guided endonucleases
US20240376451A1 (en) * 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
KR20240017367A (ko) * 2021-06-02 2024-02-07 메타지노미, 인크. 클래스 ii, v형 crispr 시스템
WO2023056291A1 (en) 2021-09-28 2023-04-06 Acrigen Biosciences Compositions and methods for nucleic acid modifications
CN117050973B (zh) * 2021-10-29 2024-07-19 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
WO2023092132A1 (en) * 2021-11-22 2023-05-25 Mammoth Biosciences, Inc. Effector proteins and uses thereof
CN116200368A (zh) * 2021-11-30 2023-06-02 上海科技大学 一种基于c2c9核酸酶的新型基因组编辑系统及其应用
AU2023209457A1 (en) * 2022-01-21 2024-08-08 Mammoth Biosciences, Inc. Effector proteins and methods of use
CN119546757A (zh) 2022-05-25 2025-02-28 宏基因组学公司 肝酶表达的补充
US12264328B2 (en) 2022-07-18 2025-04-01 ReNAgade Therapeutics Management, Inc. Gene editing components, systems, and methods of use
JP2025525569A (ja) * 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024042168A1 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024107665A1 (en) * 2022-11-14 2024-05-23 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof
TW202440913A (zh) * 2022-12-08 2024-10-16 香港商正基基因科技有限公司 Cas12蛋白、CRISPR-Cas系統及其用途
JP2026501682A (ja) * 2023-01-03 2026-01-16 エメンドバイオ・インコーポレイテッド Omni xl1~22 crisprヌクレアーゼ
WO2025003358A2 (en) * 2023-06-29 2025-01-02 UCB Biopharma SRL Novel nucleic acid targeting systems comprising rna-guided nucleases
WO2025051140A1 (zh) * 2023-09-04 2025-03-13 中国农业大学 新型CRISPR-Casσ酶和系统
CN118773168B (zh) * 2023-11-24 2025-07-25 华智生物技术有限公司 CRISPR/Cas效应蛋白HT001及系统与应用
EP4574975A1 (en) * 2023-12-20 2025-06-25 Bayer AG Compositions and methods for delivering transgenes
WO2025201316A1 (zh) * 2024-03-25 2025-10-02 深圳华大生命科学研究院 一种CRISPR-Cas系统

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9963689B2 (en) 2013-12-31 2018-05-08 The Regents Of The University Of California Cas9 crystals and methods of use thereof
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017127807A1 (en) * 2016-01-22 2017-07-27 The Broad Institute Inc. Crystal structure of crispr cpf1
US20200263190A1 (en) * 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
US20190161743A1 (en) 2016-05-09 2019-05-30 President And Fellows Of Harvard College Self-Targeting Guide RNAs in CRISPR System
KR102758434B1 (ko) * 2017-03-30 2025-01-21 고쿠리츠 다이가쿠 호진 교토 다이가쿠 게놈 편집에 의한 엑손 스키핑 유도 방법
WO2018195545A2 (en) * 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
CA3102054A1 (en) * 2017-06-05 2018-12-13 Fred Hutchinson Cancer Research Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020536502A (ja) 2017-09-07 2020-12-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子操作のためのヌクレアーゼシステム
US20190247517A1 (en) 2017-10-17 2019-08-15 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing for hemophilia a
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス,インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
EP3931313A2 (en) * 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
AU2020223370B2 (en) 2019-02-14 2023-04-20 Metagenomi Therapeutics, Inc. Enzymes with RuvC domains
CN110684823A (zh) 2019-10-23 2020-01-14 海南大学 一种基于试纸条的Cas12a酶的微生物快速诊断技术
CN110904239B (zh) 2019-12-25 2020-11-10 武汉博杰生物医学科技有限公司 肺癌相关分子标志物基因突变的检测试剂盒与检测方法
WO2021178934A1 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
GB2617658B (en) * 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
KR20230021657A (ko) 2020-05-08 2023-02-14 메타지노미, 인크. Ruvc 도메인을 포함하는 효소
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
WO2022159742A1 (en) 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
BR112023014719A2 (pt) 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
EP4281567A4 (en) 2021-01-25 2025-03-05 The Broad Institute Inc. REPROGRAMMABLE TNPB POLYPEPTIDES AND THEIR USE
BR112023018948A2 (pt) 2021-03-19 2023-10-17 Metagenomi Inc Edição multiplex com enzimas cas
KR20240017367A (ko) 2021-06-02 2024-02-07 메타지노미, 인크. 클래스 ii, v형 crispr 시스템
MX2024003007A (es) 2021-09-08 2024-03-25 Metagenomi Inc Sistemas crispr de clase ii, tipo v.
EP4399290A4 (en) 2021-09-08 2025-10-01 Metagenomi Inc CLASS II TYPE V CRISPR SYSTEMS

Also Published As

Publication number Publication date
AU2021231074A1 (en) 2022-09-29
US20220290187A1 (en) 2022-09-15
JP2025060673A (ja) 2025-04-10
KR20240036729A (ko) 2024-03-20
JP2023517041A (ja) 2023-04-21
US11713471B2 (en) 2023-08-01
US20230227857A1 (en) 2023-07-20
GB202219438D0 (en) 2023-02-01
EP4114932A2 (en) 2023-01-11
GB2617658B (en) 2024-04-17
GB2603704B (en) 2023-02-15
US12123014B2 (en) 2024-10-22
CA3174557A1 (en) 2021-09-10
EP4114932A4 (en) 2024-03-13
JP7605852B2 (ja) 2024-12-24
GB2603704A (en) 2022-08-10
AU2024200614A1 (en) 2024-04-11
KR102647766B1 (ko) 2024-03-13
GB202205584D0 (en) 2022-06-01
WO2021178933A2 (en) 2021-09-10
AU2021231074C1 (en) 2024-06-27
KR20220150329A (ko) 2022-11-10
WO2021178933A3 (en) 2021-12-23
US20240093239A1 (en) 2024-03-21
CN116096876A (zh) 2023-05-09
AU2021231074B2 (en) 2023-11-02
GB2617658A (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2022011039A (es) Sistemas crispr clase ii tipo v.
WO2024026499A3 (en) Class ii, type v crispr systems
MX2023014356A (es) Sistemas crispr de clase ii, tipo v.
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
MX2023007524A (es) Composiciones y metodos para edicion epigenetica.
MX2023006566A (es) Sistemas crispr tipo v clase 2 diseñados por ingeniería.
MX2024003007A (es) Sistemas crispr de clase ii, tipo v.
WO2019089884A3 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
WO2020185702A3 (en) Mutant taq polymerase for faster amplification
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
WO2020236972A3 (en) Non-classi engineered crispr-cas polynucleotide targeting system
MX2020004344A (es) Objetivos genéticos para el direccionamiento de fijación de nitrógeno para mejorar los rasgos de las plantas.
WO2020003006A3 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
PH12021550849A1 (en) Compositions and methods for immunotherapy
MY204767A (en) Polymerases, compositions, and methods of use
WO2023039424A3 (en) Methods and compositions for modulating a genome
WO2021055459A8 (en) Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof
BR112018004670A2 (pt) composição inoculante não aquosa, material de propagação em planta revestida, kit, planta, parte de planta, produto processado, cultura, e, método
MX2025007036A (es) Metodos y composiciones para generar alelos dominantes usando edicion del genoma
EP4700161A3 (en) Direct-to-library methods, systems, and compositions
MX2025010537A (es) Sistemas crispr de clase 2, tipo v
WO2021248023A3 (en) Compositions and methods for epigenome editing
EP4058597A4 (en) SYSTEMS, METHODS AND COMPOSITIONS FOR GENERATING MULTI-OMICS INFORMATION FROM SINGLE CELLS
WO2020198174A8 (en) Simultaneous multiplex genome editing in yeast
WO2021041001A3 (en) AUGMENTED sgRNAS AND METHODS FOR THEIR USE TO ENHANCE SOMATIC AND GERMLINE PLANT GENOME ENGINEERING